Once-monthly ibandronate

Treatments in Endocrinology

Volumn 4, Issue 6, 2005, Pages 381-387

  Dando, Toni M ^a   Noble, Stuart ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; IBANDRONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

AREA UNDER THE CURVE; ARTHRALGIA; BONE NECROSIS; CARDIOTOXICITY; CLINICAL PROTOCOL; CONSULTATION; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFORMATION; DRUG MECHANISM; DRUG MONITORING; DRUG PREFERENCE; DRUG TOLERABILITY; FLU LIKE SYNDROME; FOOD DRUG INTERACTION; GASTROINTESTINAL TOXICITY; HUMAN; LUMBAR SPINE; MYALGIA; NAUSEA; PATIENT MONITORING; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; VERTEBRA FRACTURE;

DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 28644435276     PISSN: 11756349     EISSN: 11756349     Source Type: Journal    
DOI: 10.2165/00024677-200504060-00009     Document Type: Review

References (26)

1. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94: 646-50
2. Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003 Nov 31; 9 (6): 544-64
3. Prevention and management of osteoporosis. World Health Organ Tech Rep Ser 2003; 921: i-192
4. McClung MR. Prevention and management of osteoporosis. Best Pract Res Clin Endocrinol Metab 2003; 17 (1): 53-71
5. Sebaldt RJ, Shane LG, Pham BZ, et al. Impact of non-compliance and non-persistence with daily-regimen bisphosphonates on longer-term effectiveness outcomes in patients with osteoporosis. 26th Annual Meeting of the American Society for Bone and Mineral Research; 2004 Oct 1-5; Seattle (WA)
6. Cramer JA, Amonkar MM, Hebborn A, et al. Does dosing regimen impact persistence with bisphosphonate therapy among postmenopausal osteoporotic women [abstract no. M434]. 26th Annual Meeting of the American Society for Bone and Mineral Research; 2004 Oct 1-5; Seattle (WA)
7. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphos-phonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005; 80: 856-61
8. Akesson K, Beusterien K, Hebborn A, et al. Patient preference for once-monthly over weekly bisphosphonate treatment [poster no. 315]. 5th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis; 2005 Mar 16-19; Rome
9. Richter A, Anton SF, Koch P, et al. The impact of reducing dose frequency on health outcomes. Clin Ther 2003; 25 (8): 2307-35, discussion 2306
10. Cremers SC, Pillai G, Papapoulos SE. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 2005; 44 (6): 551-70
11. Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005 Aug; 20 (8): 1315-22
12. Reginster JY, Wilson KM, Dumont E, et al. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. J Clin Pharmacol. Epub 2005 Jun 21
13. Bauss F, Russell RG. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 2004 Jun; 15 (6): 423-33
14. Papapoulos SE. Ibandronate: a potent new bisphosphonate in the management of postmenopausal osteoporosis. Int J Clin Pract 2003 Jun; 57 (5): 417-22
15. Barrett J, Worth E, Bauss F, et al. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 2004 Sep; 44 (9): 951-65
16. Pillai G, Gieschke R, Goggin T, et al. Population pharmacokinetics of ibandronate in Caucasian and Japanese post-menopausal women. Population Approach Group in Europe (PAGE); 2001 Jun 7-8; Basel
17. Ravn P, Neugebauer G, Christiansen C. Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Bone 2002 Jan; 30: 320-4
18. Roche, GlaxoSmithKline. Boniva® (ibandronate sodium) tablets: prescribing information [online]. Available from URL: http://www.fda.gov/cder [Accessed 2005 Jun 10]
19. Tanko LB, McClung MR, Schimmer RC, et al. The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast. Bone 2003 Apr; 32: 421-6
20. Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004 Aug; 19 (8): 1241-9
21. Wasnich R, Miller PD, Huss H, et al. Association between fracture efficacy and bone mineral density change with ibandronate: results from the BONE study [abstract no. P272]. Osteoporos Int 2003; 14 Suppl. 7: 76
22. Cooper C, Delmas PD, Felsenberg D, et al. Two-year efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: the MOBILE study [abstract no. OP0036]. Ann Rheum Dis 2005 Jul; 64 Suppl. III: 68
23. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000; 85: 231-6
24. Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002; 87: 1586-92
25. Felsenberg D, Miller P, Armbrecht G, et al. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2 and 3 years in postmenopausal women with osteoporosis. Bone. Epub 2005 Aug 24
26. Emkey R, Binkley N, Seidman L, et al. BALTO I: women treated for osteoporosis rate preference and convenience for once-monthly ibandronate versus once-weekly alendronate. 27th Annual Meeting of the American Society for Bone and Mineral Research; 2005 Sep 23-27; Nashville (TN)